このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

2014年10月14日 更新者:Astellas Pharma Europe Ltd.

An Exploratory Study to Evaluate Bladder Contractions in the Storage Phase (Non Voiding Activities) and Related Bladder Sensation in Healthy Females and Untreated Females With Overactive Bladder ("OAB") Using High Resolution and Conventional Urodynamics

This study aims to identify differences in bladder contractions during the storage phase (non voiding activities) between OAB subjects and healthy subjects, using high resolution urodynamics.

The study is divided into two parts:

  • PART 1: Consists of 5 females with overactive bladder
  • PART 2: Consists of 25 females with overactive bladder and 15 healthy females

Part 1 subjects will be enrolled followed by part 2 subjects. The data from part 1 subjects will be reviewed and analysed by a group of experts before starting the second part (part 2) of the study.

調査の概要

詳細な説明

The subjects will complete a total of 2 visits and a follow up telephone call (or visit at the investigator's discretion).

Upon meeting eligibility criteria subjects will be screened and complete visit at hospital (Visit 1). They will then be asked to complete procedures such micturition diary, questionnaires and if applicable discontinued their ongoing OAB medication. Upon confirmation of eligibility criteria subjects will then be enrolled and complete visit 2 within 6 to 31 days post V1. At Visit 2 subjects will complete high resolution urodynamic assessment followed by the conventional urodynamic assessment. The visit will take approximately half a day. Safety follow up phone call (or visit at investigator's discretion) will take place 4 to 6 days post visit 2.

研究の種類

介入

入学 (実際)

6

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Maastricht、オランダ、6202
        • Maastricht University Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

35年~65年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

説明

Inclusion Criteria:

OAB Subjects

  • Has history of signs and symptoms of OAB including urinary frequency, urgency or urge incontinence for greater than or equal to 3 months
  • At enrolment visit (V2) the subjects must have:

    • At least 1 episode of urgency with or without incontinence in the last 3-day micturition diary
    • Frequency of micturition greater than or equal to 8 per 24 hours period during the 3-day micturition diary period
  • At the screening visit, the subject should be either naïve to OAB treatment (e.g no prior history of medications to treat lower urinary tract symptoms (LUTS), including OAB) or currently on treatment for LUTS (including OAB) and is willing to undergo a washout period for 3 weeks

Main Exclusion criteria:

Healthy subjects

  • History of lower urinary tract symptoms (LUTS), including OAB
  • History of stress urinary incontinence, urethral sphincter incompetence and neurogenic detrusor overactivity
  • History of signs or symptoms suggestive of urinary tract infection (confirmed by positive urine analysis)
  • History of bladder outlet obstruction (not including detrusor-overactivity) for example bladder/vesicouterine pro-lapse (> grade II) or chronic obstruction
  • History of urinary tract surgery less than or equal to 6 months prior to screening
  • Has an indwelling catheter or permanent catheter fitted
  • History of pelvic area radiotherapy treatment
  • Uncontrolled diabetes mellitus
  • History of fibromyalgia
  • Pregnant or intends to become pregnant during the study or sexually active, of childbearing potential and is unwilling to utilize a reliable method of birth control (note: reliable methods are contraceptive pills of combination type, hormonal implants, injectable contraceptives, sexual abstinence or vasectomized partner)
  • Pregnancy within 6 months before screening or breast feeding within 3 months before screening
  • History of a positive hepatitis A, B surface antigen, hepatitis C antibody or HIV test result.
  • Any use of drugs of abuse within 3 months prior to screening visit.
  • History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to screening visit
  • History of drinking more than 14 units of alcohol per week (1 unit = 10 g pure alcohol = 250 ml of beer (5%) or 35 ml of spirits (35%) or 100 ml of wine (12%) within 3 months prior to screening visit
  • Is currently receiving or has a history of treatment with alpha blockers, beta receptor blockers or agonists, botulinum toxin (less than 12 months), resiniferatoxin or pelvic floor muscle relaxants less than or equal to 9 months prior to screening

Main exclusion criteria OAB subjects

  • Refer to healthy subjects exclusion criteria number 2 to 16

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:ヘルスサービス研究
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Identify objective parameters to characterize Non Voiding Activity (NVA) in healthy and OAB subjects using high resolution urodynamic assessment
時間枠:During the High resolution urodynamics (Day 1)
NVA is defined as changes of pressure in the bladder lumen. These changes are measured as detrusor pressure (Pdet) calculated from substraction of intra-abdominal pressure (Pabd) from intra-vesical pressure (Pves). All Pdet with an amplitude of at least 1cm of water, frequency below 0.2 Hz and pulse duration between 5 and 60 seconds qualify as NVA.
During the High resolution urodynamics (Day 1)

二次結果の測定

結果測定
時間枠
Identify NVA in healthy and OAB subjects using conventional urodynamic assessment
時間枠:During High resolution and conventional urodynamic (Day 1) assessments
During High resolution and conventional urodynamic (Day 1) assessments
Assess the subjects bladder sensations measured by visual analogue scale (VAS) and 5-points categorical scale (Appendix 8 & 7) during the high resolution urodynamic and conventional assessments
時間枠:During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Assess the correlation between NVA and subjects bladder sensations
時間枠:During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Explore NVA in a subgroup of subjects defined by the severity of OAB symptoms collected as background information (3-days bladder diary)
時間枠:During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Illustrate the amount of NVA detected with high resolution urodynamic test methodology compared to NVA detected with conventional urodynamic assessments
時間枠:During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)
Assess symptoms severity, bother and its impact on quality of life using: OAB-Q short form and Urogenital Distress Inventory (UDI-6) questionnaires and a 3-Day micturition bladder diary as background information to characterize the study population
時間枠:During High resolution and conventional urodynamic assessments (Day 1)
During High resolution and conventional urodynamic assessments (Day 1)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Clinical Study Manager、Astellas Pharma Europe Ltd.
  • 主任研究者:Principal Investigator、Maastricht University Medical Center, Maastricht

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2012年3月1日

一次修了 (実際)

2012年6月1日

研究の完了 (実際)

2012年6月1日

試験登録日

最初に提出

2012年2月13日

QC基準を満たした最初の提出物

2012年2月23日

最初の投稿 (見積もり)

2012年2月29日

学習記録の更新

投稿された最後の更新 (見積もり)

2014年10月15日

QC基準を満たした最後の更新が送信されました

2014年10月14日

最終確認日

2014年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 905-EC-010

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する